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No benefit of longer eradication therapy 
of Pseudomonas aeruginosa primoinfections 
in pediatric cystic fibrosis
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Abstract 
Objective: Patients with cystic fibrosis are more susceptible than members of the general population to lung infec-
tions. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deteriora-
tion of lung function if not adequately treated. This study assessed the eradication rate of P. aeruginosa primoinfec-
tions, with a protocol of inhaled tobramycin and oral ciprofloxacin over a 3 months’ period.
Results: Retrospective single-center study from June 1st, 2007 to December 31st, 2015. Inclusion of 28 pediatric 
patients (11 females, 17 males), with a total of 49 primoinfections. Overall success rate of 67.3%, which is similar or 
even inferior to figures published in the literature.
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Introduction
Airways infections in patients with cystic fibrosis (CF) 
may deteriorate their lung function, particularly those 
involving Pseudomonas aeruginosa [1]. The early detec-
tion of this pathogen is fundamental, because its phe-
notypic changes and the exacerbated inflammatory 
response across the time render its eradication more dif-
ficult [1–5].
At the pediatric CF outpatient clinic at Lausanne Uni-
versity Hospital, the first detection ever or the reacquisi-
tion of P. aeruginosa after a minimum of 6  months and 
at least three negative bacterial cultures was defined as 
“primoinfection” and was treated with inhaled tobramy-
cin and oral ciprofloxacin over 3 months. To our knowl-
edge, this is one of the longest therapeutic interventions 
described [6–11]. With this study, we wanted to deter-
mine if a longer protocol brings benefits in terms of 
eradication.
Main text
Method
Intervention
We treated P. aeruginosa primoinfections with three con-
secutive cycles of 28 days of inhaled tobramycin  (TOBI® 
by Novartis or  Bramitob® by Chiesi; 300 mg BID), with 
oral ciprofloxacin  (Ciproxin® by Bayer; 30 to 40 mg/kg/
day in two doses, maximum 1500  mg/day) during the 
first and last 21 days of the protocol (Fig. 1). We evalu-
ated the efficacy after a 6 months follow-up (3 months of 
therapy, 3  months post-therapy) by a multidisciplinary 
team (physicians, physiotherapists, dieticians, CF nurse, 
social worker and psychiatrist), with collection of mini-
mum three bacterial cultures (the latest always at the end 
of the follow-up). A success in eradication was defined 
by negative cultures for P. aeruginosa during the whole 
follow-up. A failure in eradication was defined by at least 
one positive culture for P. aeruginosa. In this case or by 
deterioration of clinical conditions of our patients, other 
therapeutic options were evaluated (for instance, intra-
venous antibiotic treatment).
Outcomes
Determination of the eradication rate of our eradica-
tion protocol. Calculation of mean ages, assessment of 
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symptoms and methods used to obtain the cultures at 
the primoinfection. Analyze of the evolution of the lung 
function and the anthropometric parameters, comparing 
the best values in the 6 months before the primoinfection 
and during the 6 months after the initiation of the eradi-
cation protocol. Assessment of most common bacterial 
coinfections at the primoinfection and at the end of the 
follow-up.
Design
Retrospective study in the pediatric CF outpatient 
clinic at Lausanne University Hospital. In a preliminary 
study in 2011, we analyzed data from 20 primoinfec-
tions treated with our eradication protocol since June 
1st, 2007, eradication rate of 80%. To confirm this result, 
according to the size of our outpatient clinic (about 60 
patients), we estimated a minimum needed of 49 pri-
moinfections (confidence interval 95%, margin of error 
5%) to gather till December 31st, 2015. Pediatric outpa-
tients (up to 18 years old), with a confirmed diagnosis of 
CF (by a positive sweat test and/or two disease-causing 
mutations) and with P. aeruginosa primoinfections were 
included. Patients with P. aeruginosa primoinfections not 
exactly treated according to the protocol, with an initial 
intra-venous antibiotic course followed by the protocol 
or with incomplete data sets were excluded.
Data
Sex, common symptoms and age at the primoinfection 
diagnosis, diagnostic methods used to obtain the cul-
tures, forced expiratory volume in 1 s (FEV1), body mass 
index (BMI) and data about the most common bacterial 
coinfections were collected in a FileMaker Pro 15 data-
base. Statistical analysis with Xlstat-Biomed 19.5 and 
Microsoft Excel 2016. According to the data distribution 
(normal or not), we used parametric (T test) or non-par-
ametric (Mann–Whitney, Wilcoxon or McNemar) tests.
Primary outcome
Our study included 28 patients (11 females, 17 males), 
with total of 49 primoinfections. 33 primoinfections suc-
cessfully treated, with an overall success rate of 67.3% 
(confidence interval 54.2–80.4%). Success rate of 78.9% 
for the girls and 60.0% for the boys, statistically different 
(p = 0.006, McNemar). However, mean number of primo-
infections between the girls (1.727) and the boys (1.765) 
not statistically different (p = 0.789, Mann–Whitney).
In the success group, 2 patients had 2 primoinfections, 
2 patients had 3 primoinfections. Moreover, 3 patients 
had 2 primoinfections successfully treated and 1 fail-
ure in eradication. In the failure group, 1 patient had 4 
primoinfections.
Secondary outcomes
Mean ages
9.3 years in the success group (SD 4.5 years) and 9.1 years 
in the failure group (SD 3.7  years), no statistical differ-
ence (p = 0.842, T test) (Table  1). According to the sex, 
10.1 years (SD 4.6 years) for the girls and 8.3 years for the 
boys (SD 4.1 years), no statistical difference (p = 0.290, T 
test).
Symptoms
27 patients in the success group (81.8%) and 14 in the 
failure group (87.5%) were symptomatic at the primoin-
fection diagnosis, no statistical difference between the 
groups (p = 0.118, McNemar). Some patients had more 
than one symptom (Table 1).
Diagnostic methods
Material for P. aeruginosa cultures was gathered in the 
majority of the cases through sputum samples, then 
through oropharyngeal swabs. No other methods were 
used (for instance, bronchoalveolar lavage). No signifi-
cant difference between these two methods (Table 1).
Follow-up period
at least 3 consecutive bacterial cultures
in minimum 6 months
Oral 
ciprofloxacin 
Oral 
ciprofloxacin 
Inhaled 
tobramycin 
Pseudom
onas aeruginosa
prim
oinfection
Fig. 1 Eradication protocol and follow-up
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Lung function evolution
We didn’t observe any significant changes in the mean 
FEV1 value before and after the eradication protocol 
(Table 1).
Anthropometric evolution
We observed an increase of the mean BMI value before 
and after the eradication protocol for the two groups, not 
statistically significant in the failure group (Table 1).
Bacterial coinfections
The physiological oropharyngeal flora was evidenced in 
most of the primoinfections through the study. The co-
pathogen observed most frequently at the primoinfection 
was Staphylococcus aureus (methicillin sensitive), fol-
lowed by Haemophilus influenzae and Stenotrophomonas 
maltophilia. At the end of the follow-up, we noticed a 
non-statistically significative diminution of these patho-
gens and a non-statistically significative emergence of 
Achromobacter xylosoxidans and Streptococcus pneumo-
niae in the success group. Some other co-pathogens were 
rare and classified as “other”. Their incidence didn’t vary 
through the study (Fig. 2).
Discussion
Our retrospective study demonstrated that a 3  months’ 
therapy in case of P. aeruginosa primoinfections brings 
no extra benefits in terms of eradication. Our overall suc-
cess rate was 67.3%. We noticed a significant difference 
between the girls (78.9%) and the boys (60.0%), attributed 
to a better compliance of the girls.
The definition of successful eradication, the dura-
tion of inhaled therapy, the addition of oral ciprofloxa-
cin and the nature of follow-up remain matter of debate 
[12]. In the United States, the CF Foundation recom-
mends 28  days of inhaled tobramycin [13]. About the 
duration of the inhaled therapy, Ratjen et al. assessed the 
time to recurrence of P. aeruginosa after 28 or 56  days 
of inhaled tobramycin. It was similar in the two groups 
(26.12  months with 28  days and 25.82  months with 
56 days). At the end of the study, 66% of patients were free 
from P. aeruginosa with 28 days and 69% with 56 days [7]. 
Gibson et al. assessed the P. aeruginosa eradication from 
the lower airways after 28 or 56 days of inhaled tobramy-
cin, with different times of follow-up. It was similar in all 
Table 1 Secondary outcomes
Among symptomatic patients, distribution of most frequent symptoms. A patient may have more than one symptom (in italics)
Success group Failure group
Primoinfections [n] 33 16
Age at diagnosis [years] 9.3 9.1
p value 0.842 (T test)
Symptoms at diagnosis [%] 81.8 87.5
p value 0.118 (McNemar)
 Cough [%] 66.7 87.5
 Upper respiratory tract infect. [%] 39.4 25.0
 Dyspnea [%] 3.0 12.5
 Fever [%] 3.0 12.5
Diagnostic methods [%]
 Sputum samples 69.7 75.0
 Oropharyngeal swab 30.3 25.0
p value 0.831 (McNemar)
Diagn. Follow-up Diagn. Follow-up
FEV1 [%]
 Mean 107.7 107.8 104.7 99.1
 Median 103 103 104 99.5
 p value 0.772 (Wilcoxon) 0.312 (T test)
BMI [kg/m2]
 Mean 16.3 16.6 16.9 17.1
 Median 15.8 16.0 16.6 16.2
 p value 0.024 (Wilcoxon) 0.083 (Wilcoxon)
Page 4 of 6Claude et al. BMC Res Notes          (2019) 12:115 
groups—globally 75% [6]. Most recently, Blanchard et al. 
analyzed a three-steps eradication strategy. In asymp-
tomatic patients with new onset of P. aeruginosa, the 
eradication rate was 76.9% after a first cycle of 28 days of 
inhaled tobramycin. Successive steps could improve the 
eradication rate [11]. The use of oral ciprofloxacin was 
assessed by Treggiari et al. They compared four different 
regimens that combined cyclic or culture-based inhaled 
tobramycin, with oral ciprofloxacin or a placebo for 
14 days. 17 patients of 133 were P. aeruginosa positive at 
the end of the study in the ciproxins’ group and 12 of 134 
in the placebos’ group [8]. The use of inhaled tobramy-
cin vs colistin was addressed by Taccetti et al. and Proes-
mann et al. [9, 10]. The first study analyzed the efficacy of 
28 days of inhaled tobramycin or colistin, with oral cip-
rofloxacin. Success in eradication was defined by succes-
sive negative cultures in 6 months and was similar among 
the groups (colistin 62.8%, tobramycin 65.2%) [9]. The 
second study compared 3 months of inhaled colistin and 
oral ciprofloxacin to 28  days of inhaled tobramycin. At 
the end of the treatment, the eradication rates were simi-
lar among the groups (colistin and ciprofloxacin 89.7%, 
tobramycin 79.3%) [10]. For the studies that assessed 
the eradication rates [6, 9–11], they were similar or even 
better than ours (67.3%). Most of these pediatric studies 
used shorter inhaled therapies [6–9, 11]. One of them 
demonstrated that the use of oral ciprofloxacin brings no 
extra benefits [8]. Others showed that the use of inhaled 
tobramycin or colistin is equivalent [9, 10]. These find-
ings are fundamental, because reducing the duration of 
the inhaled therapy, avoiding to give oral ciprofloxacin, 
having the choice between tobramycin and colistin, could 
increase the compliance of patients, decrease the risk of 
side-effects and last but not least the costs of the therapy. 
As a consequence, we decided to reduce our eradication 
protocol to 1  month of inhaled tobramycin or colistin. 
However, according to the guidelines of the Swiss Work-
ing Group of Cystic Fibrosis, our patients are still treated 
in association with oral ciprofloxacin [14].
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Our analysis of secondary outcomes revealed no sig-
nificant difference between groups in terms of age, as 
reported in a  previous study [7]. Most of our patients 
were symptomatic at the time of the diagnosis. In a 
previous  study, patients with acute lung disease were 
excluded [7]. The material used to derive P. aeruginosa 
cultures was gathered in the majority in the form of spu-
tum samples. Bronchoalveolar lavage as a “gold standard” 
for identification of lower respiratory tract infections in 
patients with cystic fibrosis was recently discussed [15–
18]. The results obtained with bronchoalveolar lavage are 
similar to those obtained with induced sputum [19]. In 
addition to the technical issues of bronchoalveolar lavage 
(general anesthesia in children), samples obtained vary 
greatly, depending on localization within the lungs [20–
22]. As reported previously, evaluation of the lung func-
tion (FEV1) before implementation of the eradication 
protocol were similar to those obtained after its comple-
tion [7]. We noticed an increase in BMI over the course 
of the study, but not statistically significant because of 
the failure group. Regarding the co-pathogens, one study 
showed that bacterial co-infections at the time of pri-
moinfection were not a risk factor for failed eradication 
[11]. The co-pathogens observed most frequently at the 
primoinfection diagnosis were S. aureus and H. influen-
zae. This observation is similar to findings reported pre-
viously [6–9]. In our study, S. maltophilia was the third 
most frequent pathogen identified at the primoinfection 
diagnosis. However, previous studies reported its iden-
tification during the follow-up [8, 9]. We observed the 
emergence of A. xylosoxidans and S. pneumoniae in some 
cases, but this trend was not statistically significant.
Conclusion
The overall eradication rate of P. aeruginosa primoinfec-
tion with use of our 3 months’ protocol was 67.3%. This 
figure is similar or even inferior to those reported pre-
viously, despite our study’s use of a longer duration of 
inhaled therapy with tobramycin as well as combination 
treatment with oral ciprofloxacin. These findings eluci-
date the nature of patient compliance, side effects and 
economic considerations.
Limitations
• Small sample size and retrospective design of our 
study, that prevented a stratification of our patients 
and risk to draw general conclusions for bigger 
cohorts followed in CF centers across the world. 
However, our conclusions are supported by other 
studies which use shorter protocols [6–9, 11].
• Comparison across studies is difficult because of 
methodological discrepancies and lack of standard-
ized definitions.
• During the 6 months’ follow-up, patients are group-
ing according to the result of their P. aeruginosa cul-
tures. Keeping outpatients in a positive cohort for 
such a long time can lead to cross-infections.
• No genotyping of P. aeruginosa, in order to separate 
precisely a new primoinfection and the persistence of 
the pathogen.
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CF: cystic fibrosis.
Authors’ contributions
Design of the study: CF and HGM. Acquisition and interpretation of the data: 
CF and HGM. Redaction and revision of the article: CF, RI and HGM. Corre-
sponding author: CF. All authors agree with a publication in the BMC Research 
Notes. All authors read and approved the final manuscript.
Author details
1 Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzer-
land. 2 Department of Pediatrics, Respiratory Unit, Centre Hospitalier Universi-
taire Vaudois, Lausanne, Switzerland. 
Acknowledgements
We would like to acknowledge the patients and their families, the Faculty of 
Biology and Medicine of the University of Lausanne and the Department of 
Pediatrics of the Centre Hospitalier Universitaire Vaudois in Lausanne.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
All the data analyzed in our study are exposed in the text, figures and tables.
Consent to publish
Not applicable.
Ethics approval and consent to participate
Two ethics approvals were obtained (the first for the preliminary study on 
July 18th, 2011 and the second for the continuation of the study on July 18th, 
2014; protocol number CER-VD 236/14) by the Ethics Committee of Canton 
Vaud (Communauté de travail des Commissions d’éthique de la recherche 
en Suisse, Commission cantonale d’éthique sur l’être humain, Av. de Chailly 
23, 1012 Lausanne, Vaud, Switzerland). In retrospective studies as ours, the 
Ethics Committee of Canton Vaud allows to use health-related personal data 
without oral or written consent based on article 34a of the Swiss Federal Act 
on Research involving Human Beings.
Funding
None to declare.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 29 December 2018   Accepted: 22 February 2019
Page 6 of 6Claude et al. BMC Res Notes          (2019) 12:115 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
References
 1. Stuart B, Lin JH, Mogayzel PJ Jr. Early eradication of Pseudomonas aerugi-
nosa in patients with cystic fibrosis. Paediatr Respir Rev. 2010;11(3):177–
84. https ://doi.org/10.1016/j.prrv.2010.05.003.
 2. Bush A. Decisions facing the cystic fibrosis clinician at first isolation of 
Pseudomonas aeruginosa. Paediatr Respir Rev. 2002;3(1):82–8. https ://doi.
org/10.1053/prrv.2002.0193.
 3. Bassinet L. Strategy of antibiotic therapy in the course of chronic Pseu-
domonas aeruginosa infection. Rev Mal Respir. 2003;20(2 Pt 2):S118–28.
 4. Koch C, Cuppens H, Rainisio M, Madessani U, Harms H, Hodson M, Mas-
tella G, Navarro J, Strandvik B, McKenzie S, et al. European Epidemiologic 
Registry of Cystic Fibrosis (ERCF): comparison of major disease mani-
festations between patients with different classes of mutations. Pediatr 
Pulmonol. 2001;31(1):1–12.
 5. Eber E, Zach MS. Pseudomonas aeruginosa infection in cystic fibrosis: 
prevent, eradicate or both? Thorax. 2010;65(10):849–51. https ://doi.
org/10.1136/thx.2010.13889 1.
 6. Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso 
FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, et al. Duration 
of treatment effect after tobramycin solution for inhalation in young 
children with cystic fibrosis. Pediatr Pulmonol. 2007;42(7):610–23. https ://
doi.org/10.1002/ppul.20625 .
 7. Ratjen F, Munck A, Kho P, Angyalosi G, ELITE Study Group. Treatment of 
early Pseudomonas aeruginosa infection in patients with cystic fibrosis: 
the ELITE trial. Thorax. 2010;65(4):286–91. https ://doi.org/10.1136/
thx.2009.12165 7.
 8. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, 
Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, et al. Comparative 
efficacy and safety of 4 randomized regimens to treat early Pseudomonas 
aeruginosa infection in children with cystic fibrosis. Arch Pediatr 
Adolesc Med. 2011;165(9):847–56. https ://doi.org/10.1001/archp ediat 
rics.2011.136.
 9. Taccetti G, Bianchini E, Cariani L, Buzzetti R, Costantini D, Trevisan F, Zava-
taro L, Campana S, Italian Group for P aeruginosa Eradication in Cystic 
Fibrosis. Early antibiotic treatment for Pseudomonas aeruginosa eradica-
tion in patients with cystic fibrosis: a randomised multicentre study 
comparing two different protocols. Thorax. 2012;67(10):853–9. https ://
doi.org/10.1136/thora xjnl-2011-20083 2.
 10. Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K. 
Comparison of two treatment regimens for eradication of Pseudomonas 
aeruginosa infection in children with cystic fibrosis. J Cyst Fibros. 
2013;12(1):29–34. https ://doi.org/10.1016/j.jcf.2012.06.001.
 11. Blanchard AC, Horton E, Stanojevic S, Taylor L, Waters V, Ratjen F. Effective-
ness of a stepwise Pseudomonas aeruginosa eradication protocol in 
children with cystic fibrosis. J Cyst Fibros. 2017;16(3):395–400. https ://doi.
org/10.1016/j.jcf.2017.01.007.
 12. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseu-
domonas aeruginosa in people with cystic fibrosis. In: Cochrane database 
of systematic reviews. John Wiley & Sons, Ltd; 2017. http://onlin elibr ary.
wiley .com/doi/10.1002/14651 858.CD004 197.pub5/abstr act. https ://doi.
org/10.1002/14651 858.cd004 197.pub5. Accessed 1 Nov 2017.
 13. Mogayzel PJ, Naureckas ET, Robinson KA, Brady C, Guill M, Lahiri T, Lubsch 
L, Matsui J, Oermann CM, Ratjen F, et al. Cystic Fibrosis Foundation pul-
monary guideline. Pharmacologic approaches to prevention and eradica-
tion of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 
2014;11(10):1640–50. https ://doi.org/10.1513/annal sats.20140 4-166oc .
 14. Regamey N. Treatment of Pseudomonas aeruginosa (PA) infection 
in CF patients, Swiss Working Group Cystic Fibrosis (SWGCF) proto-
col—30.06.2009. 2018.
 15. Ramsey BW, Wentz KR, Smith AL, Richardson M, Williams-Warren J, 
Hedges DL, Gibson R, Redding GJ, Lent K, Harris K. Predictive value of oro-
pharyngeal cultures for identifying lower airway bacteria in cystic fibrosis 
patients. Am Rev Respir Dis. 1991;144(2):331–7. https ://doi.org/10.1164/
ajrcc m/144.2.331.
 16. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. 
Bronchoalveolar lavage or oropharyngeal cultures to identify lower 
respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol. 
1996;21(5):267–75. https ://doi.org/10.1002/(SICI)1099-0496(19960 
5)21:5%3c267 :AID-PPUL1 %3e3.0.CO;2-K.
 17. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, 
Hiatt P, McCoy K, McNamara S, Ramsey B, et al. Diagnostic accuracy of 
oropharyngeal cultures in infants and young children with cystic fibrosis. 
Pediatr Pulmonol. 1999;28(5):321–8.
 18. Aaron SD, Kottachchi D, Ferris WJ, Vandemheen KL, Denis MLS, Plouffe 
A, Doucette SP, Saginur R, Chan FT, Ramotar K. Sputum versus bron-
choscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic 
fibrosis. Eur Respir J. 2004;24(4):631–7. https ://doi.org/10.1183/09031 
936.04.00049 104.
 19. Blau H, Linnane B, Carzino R, Tannenbaum E-L, Skoric B, Robinson PJ, 
Robertson C, Ranganathan SC. Induced sputum compared to bronchoal-
veolar lavage in young, non-expectorating cystic fibrosis children. J Cyst 
Fibros. 2014;13(1):106–10. https ://doi.org/10.1016/j.jcf.2013.05.013.
 20. Gutierrez JP, Grimwood K, Armstrong DS, Carlin JB, Carzino R, Olinsky A, 
Robertson CF, Phelan PD. Interlobar differences in bronchoalveolar lavage 
fluid from children with cystic fibrosis. Eur Respir J. 2001;17(2):281–6.
 21. Willner D, Haynes MR, Furlan M, Schmieder R, Lim YW, Rainey PB, Rohwer 
F, Conrad D. Spatial distribution of microbial communities in the cystic 
fibrosis lung. ISME J. 2012;6(2):471–4. https ://doi.org/10.1038/ismej 
.2011.104.
 22. Gilchrist FJ, Salamat S, Clayton S, Peach J, Alexander J, Lenney W. 
Bronchoalveolar lavage in children with cystic fibrosis: how many 
lobes should be sampled? Arch Dis Child. 2011;96(3):215–7. https ://doi.
org/10.1136/adc.2009.17761 8.
